Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Research article

Detection of antibodies directed at M. hyorhinis p37 in the serum of men with newly diagnosed prostate cancer

Cydney Urbanek1, Steve Goodison2, Myron Chang3, Stacy Porvasnik1, Noburo Sakamoto1, Chen-zhong Li4, Susan K Boehlein5 and Charles J Rosser1*

Author Affiliations

1 Department of Urology, The University of Florida, Gainesville, Florida, 32610, USA

2 Department of Surgery, The University of Florida, Jacksonville, Florida, 32209, USA

3 Department of Biostatistics, The University of Florida, Gainesville, Florida, 32610, USA

4 Department of Biomedical Engineering, Florida International University, Miami, Florida, 33174, USA

5 Department of Biochemistry, The University of Florida, Gainesville, Florida, 32610, USA

For all author emails, please log on.

BMC Cancer 2011, 11:233  doi:10.1186/1471-2407-11-233

Published: 10 June 2011

Abstract

Background

Recent epidemiologic, genetic, and molecular studies suggest infection and inflammation initiate certain cancers, including cancers of the prostate. Over the past several years, our group has been studying how mycoplasmas could possibly initiate and propagate cancers of the prostate. Specifically, Mycoplasma hyorhinis encoded protein p37 was found to promote invasion of prostate cancer cells and cause changes in growth, morphology and gene expression of these cells to a more aggressive phenotype. Moreover, we found that chronic exposure of benign human prostate cells to M. hyorhinis resulted in significant phenotypic and karyotypic changes that ultimately resulted in the malignant transformation of the benign cells. In this study, we set out to investigate another potential link between mycoplasma and human prostate cancer.

Methods

We report the incidence of men with prostate cancer and benign prostatic hyperplasia (BPH) being seropositive for M. hyorhinis. Antibodies to M. hyorhinis were surveyed by a novel indirect enzyme-linked immunosorbent assay (ELISA) in serum samples collected from men presenting to an outpatient Urology clinic for BPH (N = 105) or prostate cancer (N = 114) from 2006-2009.

Results

A seropositive rate of 36% in men with BPH and 52% in men with prostate cancer was reported, thus leading us to speculate a possible connection between M. hyorhinis exposure with prostate cancer.

Conclusions

These results further support a potential exacerbating role for mycoplasma in the development of prostate cancer.

Keywords:
Mycoplasma hyorhinis; ELISA; cancer; prostate